on NOVACYT (EPA:ALNOV)
Change within the Novacyt Board of Directors
On May 7, 2026, Novacyt SA, a company specializing in clinical diagnostics, announced the resignation of Dr. Joanne Mason. She is leaving her position as Chief Scientific Officer and Board Member to explore other professional opportunities.
Lyn Rees, CEO of Novacyt, praised Joanne Mason's key role over her six years in shaping the company's scientific strategy and strengthening its R&D. Her leadership has had a significant impact on Novacyt. The company expresses its gratitude and wishes her success in her future endeavors.
Novacyt continues its international operations, with offices in several countries and a commercial presence in more than 65 countries, including the recent expansion into Australia.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NOVACYT news